TP53 and prostate cancer: Treatment with MI-219 (Figure 8) induced p53 accumulation and up-regulation of MDM2, p21, and PUMA, three p53-target gene products, in SJSA-1 (osteosarcoma), LNCaP and 22Rv1 (prostate cancer) cell lines with wild-type p53 in dose dependant manner [69].